GASTROESOPHAGEAL-JUNCTION CANCER

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study tests a drug called AZD0901 in 33 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The cancer must have a specific protein (Claudin18.2). The goal is to see if the drug can shrink tumors and how safe it is. Pa…

This study tests a new drug called bemarituzumab combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be cured by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 72 adults will…

This study tests a new drug called TST001, an antibody that targets a protein (CLDN18.2) found on some cancer cells. It is for people with advanced solid tumors, including stomach, gastroesophageal junction, and pancreatic cancers. The trial aims to find safe doses and see how we…

This study is for people with HER2-positive esophageal or stomach cancer who have finished chemoradiation and surgery but still had some cancer cells left. It tests whether a year-long combination of two drugs, trastuzumab deruxtecan (Enhertu) and nivolumab, can safely prevent th…

This early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, es…

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…